The clinical trials for safety and usefulness of chronic hepatitis therapeutics,agent 3-oxygelmillpropionic acid polymer for the advanced and recurrent colorectal cancer of having the existing chemotherapeutic refractory or intolerance.(Phase 1 test)

ABSTRACT: Interventions: The dose of Seroshion is 1 capsule (10mg) /time after each meal (3 times/day,30mg/day). The administration period is six months. Primary outcome(s): Safety Study Design: Single arm Non-randomized

DISEASE(S): The Advanced And Recurrent Colorectal Cancer Of Having The Refractory Or Intolerance Of Existing Chemotherapy

PROVIDER: 2637391 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR